Update on stents: recent studies on the TAXUS stent system in small vessels.
Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It remains controversial whether BMS placement in small vessels has an advantage over balloon angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents (DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly impacted interventional cardiology by significantly reducing restenosis and the need for repeat revascularization. Therefore, it was also expected that DES could substantially reduce restenosis in smaller vessels. However, even in the DES era, small vessel size remains an independent predictor of angiographic and clinical restenosis. To date, only a few studies systematically investigate the clinical effect of DES placement in small vessels. In addition, some potential issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. In order to (i) establish the superiority of DES over BMS; (ii) verify the efficacy and safety of DES; and (iii) critically assess the superiority of one DES over the other in patients with small coronary arteries, further multicenter, randomized clinical trials with larger sample size are warranted.
Tanimoto
Shuzou
S
Thoraxcenter, Erasmus Medical Center, Rotterdam,The Netherlands.
Daemen
Joost
J
Serruys
Patrick W
PW
D001808:Blood Vessels / Q000033:anatomy & histology; D023903:Coronary Restenosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D015607:Stents
D017239:Paclitaxel; D020123:Sirolimus